Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer.
circulating tumor cells
metastasis-free survival
overall survival
prognosis
prostate cancer
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
30 Mar 2023
30 Mar 2023
Historique:
received:
10
03
2023
revised:
23
03
2023
accepted:
28
03
2023
medline:
28
4
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
The aim of the present study was to verify whether the baseline circulating tumor cell (CTC) count might serve as a predictor of overall survival (OS) and metastasis-free survival (MFS) in patients with high-risk prostate cancer (PCa) during a follow-up period of at least 5 years. CTCs were enumerated using three different assay formats in 104 patients: the CellSearch
Identifiants
pubmed: 37108995
pii: jpm13040608
doi: 10.3390/jpm13040608
pmc: PMC10144132
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Cancer Res Clin Oncol. 2014 Dec;140(12):2157-62
pubmed: 25028119
Oncotarget. 2017 Mar 13;8(42):71447-71455
pubmed: 29069718
J Urol. 2018 Jun;199(6):1494-1501
pubmed: 29339080
Lancet Oncol. 2009 Mar;10(3):233-9
pubmed: 19213602
Eur Urol. 2016 Nov;70(5):862-874
pubmed: 27289567
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Anticancer Res. 2014 Nov;34(11):6705-10
pubmed: 25368278
Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1904-13
pubmed: 19505924
J Clin Oncol. 2014 Apr 10;32(11):1136-42
pubmed: 24616308
J Clin Oncol. 2015 Mar 1;33(7):723-31
pubmed: 25624429
Cancer Treat Rev. 2017 Feb;53:79-97
pubmed: 28088073
Clin Cancer Res. 2004 Oct 15;10(20):6897-904
pubmed: 15501967
Biomedicines. 2021 Sep 08;9(9):
pubmed: 34572366
Anticancer Res. 2015 Oct;35(10):5679-85
pubmed: 26408743
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Clin Chem. 2019 Jan;65(1):87-99
pubmed: 30602476
J Clin Oncol. 2018 Feb 20;36(6):572-580
pubmed: 29272162
Expert Rev Mol Diagn. 2015;15(11):1411-7
pubmed: 26390240
J Clin Oncol. 2016 Sep 1;34(25):3005-13
pubmed: 27400947
J Clin Oncol. 2018 Jun 1;36(16):1631-1641
pubmed: 29504847
Sci Rep. 2016 Dec 21;6:39736
pubmed: 28000772
Urol Oncol. 2016 Nov;34(11):483.e9-483.e16
pubmed: 27658563
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Eur Urol. 2014 Jan;65(1):124-37
pubmed: 24207135
Crit Rev Oncol Hematol. 2012 Mar;81(3):241-56
pubmed: 21680196
EXCLI J. 2021 Nov 19;20:1585-1596
pubmed: 34924906
Eur Urol. 2017 Feb;71(2):168-171
pubmed: 27522164
Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):
pubmed: 29311132
J Clin Oncol. 2008 Jul 1;26(19):3213-21
pubmed: 18591556
J Urol. 2008 Jun;179(6):2187-91; discussion 2191
pubmed: 18423725
J Clin Oncol. 2015 Apr 20;33(12):1348-55
pubmed: 25800753
Cancers (Basel). 2020 Jan 09;12(1):
pubmed: 31936460
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Med Clin North Am. 2017 Jul;101(4):787-806
pubmed: 28577627
Urology. 2013 Jun;81(6):1303-7
pubmed: 23622774
Lancet Oncol. 2015 Mar;16(3):338-48
pubmed: 25701170